Skip to content Skip to footer
Subscribe Now

NEWS

Merck new
Merck Receives the FDA Approval for Keytruda and Keytruda Qlex, Plus CT ± Avastin to Treat PD-L1+ Pt-Resistant Ovarian Carcinoma
Shots: The US FDA has approved Keytruda/Keytruda Qlex + paclitaxel ± Avastin for the treatment of adults with PD-L1+ (CPS ≥1) Pt-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma, who have received 1 or 2 prior systemic therapy Approval was based on the P-III (KEYNOTE-B96/ENGOT-ov65) trial data assessing Keytruda (400mg, IV, Q6W) with CT…
February 12, 2026
Madrigal Pharmaceutical Forges ~$4.46B siRNA Deal with Ribo Life Science to Expand Genetically Targeted MASH Pipeline
Shots: Madrigal has entered into an exclusive global license agreement with Suzhou Ribo Life Science & its subsidiary Ribocure Pharmaceuticals for 6 preclinical siRNA programs in metabolic dysfunction-associated steatohepatitis (MASH) The deal allows Madrigal to pair a targeted gene-silencing siRNA approach with Rezdiffra to assess whether genetically reducing disease drivers can enhance its therapeutic impact,…
February 11, 2026
OrsoBio Reports P-IIa Trial Data on TLC-2716 in Severe Hypertriglyceridemia and Metabolic Liver Disease
Shots: OrsoBio has reported topline P-IIa PoC trial data assessing TLC-2716 (6 or 12mg, QD, PO) vs PBO in 30 overweight pts with severe hypertriglyceridemia & metabolic dysfunction–associated steatotic liver disease (MASLD) The study met its 1EP, showing statistically significant reductions in fasting triglycerides & remnant cholesterol, plus improved liver fat by MRI-PDFF, with stronger lipid…
February 11, 2026
THX Pharma Grants Biocodex Licenses for Batten-1 and TX01 in Rare Diseases
Shots: THX has granted Biocodex an exclusive global license to develop & commercialize Batten-1 for juvenile Batten disease (CLN3), along with exclusive US & Canada rights to develop & commercialize TX01 for Gaucher & Niemann-Pick type C disease As per the deal, THX will lead clinical development with financial & scientific support from Biocodex, which will…
February 11, 2026
Insilico Medicine and CMS Enter Multiple Collaborations to Advance Therapeutics in CNS and Autoimmune Indications
Shots: Insilico Medicine has entered into multiple AI-powered drug discovery collaborations with CMS, focusing on advancing therapeutic programs across CNS & autoimmune disease indications As per the deal, Insilico will leverage its Pharma.AI platform for target discovery & small-molecule design & optimization, while CMS will lead clinical development, regulatory strategy, trials, & commercialization Under the…
February 11, 2026
Load more